Moreover, lenalidomide has been shown to induce the degradation of Ikaros and Aiolos, two transcription factors repressing IL-2 production in T cells [195] and concomitantly to up-regulate the expression of the NKG2D, DNAM-1 activating receptor, and ligands MICA and PVR/CD155 in human multiple myeloma (MM) cells [196]. Here, IL2 is linked to Miyoshi myopathy.